Total Payments
$393,347
2024 Payments
$38,062
Companies
14
Transactions
449
Medicare Patients
1,537
Medicare Billing
$194,808
Payment Breakdown by Category
Other$206,712 (52.6%)
Research$120,243 (30.6%)
Consulting$31,080 (7.9%)
Travel$23,101 (5.9%)
Food & Beverage$12,042 (3.1%)
Education$169.97 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $176,392 | 69 | 44.8% |
| Unspecified | $120,243 | 53 | 30.6% |
| Consulting Fee | $31,080 | 11 | 7.9% |
| Travel and Lodging | $23,101 | 40 | 5.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $12,860 | 5 | 3.3% |
| Food and Beverage | $12,042 | 246 | 3.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $9,400 | 4 | 2.4% |
| Honoraria | $8,060 | 7 | 2.0% |
| Education | $169.97 | 14 | 0.0% |
Payments by Type
General
$273,105
396 transactions
Research
$120,243
53 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Intercept Pharmaceuticals, Inc. | $135,886 | 85 | $0 (2024) |
| ABBVIE INC. | $104,316 | 152 | $0 (2024) |
| Gilead Sciences, Inc. | $98,061 | 133 | $0 (2024) |
| Merck Sharp & Dohme LLC | $25,322 | 45 | $0 (2024) |
| Intercept Pharma Europe Ltd. | $17,018 | 3 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $10,362 | 5 | $0 (2024) |
| Eli Lilly and Company | $1,284 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $312.75 | 5 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $305.07 | 12 | $0 (2021) |
| Madrigal Pharmaceuticals | $250.08 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,062 | 33 | Gilead Sciences, Inc. ($12,442) |
| 2023 | $62,671 | 50 | INTERCEPT PHARMACEUTICALS, INC. ($34,380) |
| 2022 | $40,417 | 49 | INTERCEPT PHARMACEUTICALS, INC. ($20,798) |
| 2021 | $45,370 | 50 | Intercept Pharmaceuticals, Inc. ($23,657) |
| 2020 | $41,864 | 48 | Intercept Pharmaceuticals, Inc. ($19,663) |
| 2019 | $52,858 | 47 | Intercept Pharmaceuticals, Inc. ($28,805) |
| 2018 | $52,631 | 72 | AbbVie, Inc. ($21,763) |
| 2017 | $59,474 | 100 | Gilead Sciences Inc ($32,620) |
All Payment Transactions
449 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $117.69 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,830.00 | General |
| Category: HCV | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: HCV | ||||||
| 11/26/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: VIROLOGY | ||||||
| 11/20/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 11/20/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Rare Disease | ||||||
| 10/28/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,830.00 | General |
| Category: HCV | ||||||
| 10/24/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $122.04 | General |
| Category: HCV | ||||||
| 10/23/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $116.34 | General |
| Category: LIVER DISEASE | ||||||
| 09/24/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: LIVER DISEASE | ||||||
| 09/19/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 09/19/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Rare Disease | ||||||
| 07/25/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $540.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 06/21/2024 | Ipsen Biopharmaceuticals, Inc | Bylvay (Drug), IQIRVO | Education | In-kind items and services | $20.00 | General |
| Category: Gastroenterology | ||||||
| 06/12/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,240.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 06/12/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 05/31/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VIROLOGY | ||||||
| 05/30/2024 | Olympus Latin America, Inc. | EVIS EXERA III COLONOVIDEOSCOPE (Device) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: Gastroenterology | ||||||
| 05/23/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,830.00 | General |
| Category: HCV | ||||||
| 05/21/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $116.67 | General |
| Category: HCV | ||||||
| 05/10/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: VIROLOGY | ||||||
| 05/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.82 | General |
| 05/03/2024 | ABBVIE INC. | HUMIRA (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: IMMUNOLOGY | ||||||
| 04/30/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 04/29/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,830.00 | General |
| Category: HCV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | INTERCEPT PHARMACEUTICALS, INC. | $65,501 | 27 |
| 1011866 | INTERCEPT PHARMACEUTICALS, INC. | $21,295 | 10 |
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | Intercept Pharma Europe Ltd. | $17,018 | 3 |
| 1011866 | Intercept Pharmaceuticals, Inc. | $15,144 | 12 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF BARICITINIB (LY3009104) IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WHO HAVE AN INADEQUATE RESPONSE OR ARE INTOLERANT TO UDCA | Eli Lilly and Company | $1,284 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 376 | 447 | $68,414 | $48,412 |
| 2022 | 9 | 373 | 445 | $65,725 | $47,362 |
| 2021 | 8 | 399 | 466 | $72,176 | $54,505 |
| 2020 | 8 | 389 | 504 | $61,108 | $44,528 |
Total Patients
1,537
Total Services
1,862
Medicare Billing
$194,808
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 114 | 168 | $21,587 | $14,111 | 65.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 27 | 27 | $10,376 | $8,058 | 77.7% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 70 | 81 | $8,600 | $6,502 | 75.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 56 | 56 | $9,377 | $6,101 | 65.1% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Office | 2023 | 24 | 24 | $8,287 | $6,018 | 72.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 11 | 11 | $5,073 | $3,676 | 72.5% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Office | 2023 | 60 | 66 | $3,842 | $2,949 | 76.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 14 | $1,271 | $996.94 | 78.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 110 | 165 | $21,427 | $15,034 | 70.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 32 | 32 | $12,876 | $9,703 | 75.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 56 | 56 | $9,522 | $6,563 | 68.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2022 | 14 | 14 | $6,730 | $4,837 | 71.9% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Office | 2022 | 16 | 16 | $5,741 | $4,257 | 74.2% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Office | 2022 | 58 | 66 | $3,845 | $3,029 | 78.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 24 | $2,218 | $1,440 | 64.9% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 50 | 58 | $1,841 | $1,304 | 70.8% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2022 | 14 | 14 | $1,526 | $1,196 | 78.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 106 | 140 | $18,066 | $13,044 | 72.2% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2021 | 33 | 33 | $13,308 | $10,500 | 78.9% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Office | 2021 | 31 | 31 | $11,116 | $8,346 | 75.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 62 | 62 | $10,564 | $7,786 | 73.7% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Office | 2021 | 15 | 16 | $7,683 | $5,932 | 77.2% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Office | 2021 | 70 | 82 | $4,871 | $3,897 | 80.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 39 | 54 | $4,985 | $3,759 | 75.4% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 43 | 48 | $1,584 | $1,240 | 78.3% |
About Dr. Federico Rodriguez Perez, MD
Dr. Federico Rodriguez Perez, MD is a Hepatology healthcare provider based in San Juan, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639143480.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Federico Rodriguez Perez, MD has received a total of $393,347 in payments from pharmaceutical and medical device companies, with $38,062 received in 2024. These payments were reported across 449 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($176,392).
As a Medicare-enrolled provider, Rodriguez Perez has provided services to 1,537 Medicare beneficiaries, totaling 1,862 services with total Medicare billing of $194,808. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Other Specialties Gastroenterology
- Location San Juan, PR
- Active Since 02/16/2006
- Last Updated 03/08/2017
- Taxonomy Code 207RI0008X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639143480
Products in Payments
- OCALIVA (Drug) $152,904
- Epclusa (Drug) $75,518
- MAVYRET (Drug) $50,258
- Mavyret (Drug) $48,316
- IQIRVO (Drug) $10,342
- ZEPATIER (Drug) $5,634
- Vosevi (Drug) $3,585
- Amitiza (Drug) $250.78
- RINVOQ (Biological) $174.45
- ZEPOSIA (Drug) $149.99
- OPDIVO (Biological) $144.45
- RESMETIROM (Drug) $133.74
- EVIS EXERA III COLONOVIDEOSCOPE (Device) $124.95
- REZDIFFRA (Drug) $116.34
- RENFLEXIS (Biological) $98.04
- Humira (Biological) $96.02
- CREON (Drug) $79.88
- Viekira (Drug) $71.72
- Fibroscan (Device) $50.00
- Motegrity (Drug) $41.88
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.